Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials

Epidemiology

Volumn 27, Issue 1, 2016, Pages 143-151

  Zhao, Xiahong ^a   Fang, Vicky J ^b   Ohmit, Suzanne E ^c   Monto, Arnold S ^c   Cook, Alex R ^a,d   Cowling, Benjamin J ^b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF MICHIGAN   (United States)

^d YALE NUS COLLEGE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ADULT; FEMALE; HONG KONG; IMMUNOLOGY; INCIDENCE; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HONG KONG; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 84949623334     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000402     Document Type: Article

References (28)

1. Couch RB, Kasel JA, Immunity to influenza in man. Annu Rev Microbiol 1983 37 529 549
2. Hobson D, Curry RL, Beare AS, Ward-Gardner A, The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972 70 767 777
3. Potter CW, Oxford JS, Determinants of immunity to influenza infection in man. Br Med Bull 1979 35 69 75
4. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M, Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010 375 1100 1108
5. Skowronski DM, Tweed SA, De Serres G, Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008 197 490 502
6. Barclay VC, Smieszek T, He J, Positive network assortativity of influenza vaccination at a high school: implications for outbreak risk and herd immunity. PLoS One 2014 9 e87042
7. Chow A, Ma S, Ling AE, Chew SK, Influenza-associated deaths in tropical Singapore. Emerg Infect Dis 2006 12 114 121
8. Tamerius JD, Shaman J, Alonso WJ, Environmental predictors of seasonal influenza epidemics across temperate and tropical climates. PLoS Pathog 2013 9 e1003194
9. Center for Biologics Evaluation and Research Vaccines guidances-guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm. Accessed August 26, 2014
10. Ng S, Fang VJ, Ip DKM, Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis 2013 jit372
11. Monto AS, Ohmit SE, Petrie JG, Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009 361 1260 1267
12. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS, Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011 204 1879 1885
13. National Institute for Medical Research Report Prepared for the WHO Annual Consultation on the Composition of Influenza Vaccine for the Southern Hemisphere 2010 London National Institute for Medical Research
14. Wong JY, Wu P, Nishiura H, Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong. Am J Epidemiol 2013 177 834 840
15. Michigan Influenza Surveillance Summary 2007-2008 Influenza Season. Available at: http://www.michigan.gov/documents/mdch/2007-2008-Influenza-Season-Summary-339792-7.pdf. Accessed June 23, 2014
16. Kelly HA, Sullivan SG, Grant KA, Fielding JE, Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respir Viruses 2013 7 729 737
17. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB, Bayesian Data Analysis 2013 3rd ed Boca Raton, FL CRC Press
18. Breslow NE, Analysis of survival data under the proportional hazards model. Int Stat Rev Rev Int Stat 1975 43 45
19. Geweke J, Bernardo JM, Berger JO, Dawid AP, Smith AFM, Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments. Bayesian Statistics 4: Proceedings of the Fourth Valencia International Meeting 1992 Oxford Oxford University Press 163 193. In
20. Liu JS, Monte Carlo Strategies in Scientific Computing 2004 New York, NY Springer-Verlag
21. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS, Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011 203 1309 1315
22. R Core Team R: A Language and Environment for Statistical Computing 2014 Vienna, Austria R Foundation for Statistical Computing. Available at: http://www.R-project.org/
23. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW, The H1N1pdm serology working group. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses 2013 7 872 886
24. Wu JT, Ho A, Ma ES, Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med 2011 8 e1001103
25. Hancock K, Veguilla V, Lu X, Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009 361 1945 1952
26. Hosmer DW, Lemeshow S, May S, Applied Survival Analysis: Regression Modeling of Time to Event Data 2008 2nd ed Hoboken, NJ Wiley-Interscience
27. Hsu JP, Zhao X, Chen MI-C, Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore. BMC Infect Dis 2014 14 414
28. Longini IM, Halloran ME, Nizam A, Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 2000 18 1902 1909